Evidence map›Paper›PMID 41073374›Full record

ArticleNature communications2025

Experimental glycopeptide antibiotic EVG7 prevents recurrent Clostridioides difficile infection by sparing members of the Lachnospiraceae family.

Elma Mons, Jannie G E Henderickx, Ingrid M J G Sanders, Anusca G Rader, Caroline E Perkins, Florence M Stel, Emma van Groesen, Wiep Klaas Smits, Casey M Theriot, Nathaniel I Martin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Elma MonsBiological Chemistry Group, Institute of Biology Leiden, Leiden University, Leiden, Netherlands.ORCID http://orcid.org/0000-0003-1105-6424
Jannie G E HenderickxCenter for Microbiome Analyses and Therapeutics, Leiden University Center for Infectious Diseases (LUCID), Leiden University Medical Center, Leiden, Netherlands.ORCID http://orcid.org/0000-0001-6533-0324
Ingrid M J G SandersExperimental Bacteriology Group, Leiden University Center for Infectious Diseases (LUCID), Leiden University Medical Center, Leiden, Netherlands.
Anusca G RaderExperimental Bacteriology Group, Leiden University Center for Infectious Diseases (LUCID), Leiden University Medical Center, Leiden, Netherlands.ORCID http://orcid.org/0000-0002-4889-3691
Caroline E PerkinsDepartment of Population Health and Pathobiology, College of Veterinary Medicine, NC State University, Raleigh, NC, USA.
Florence M StelBiological Chemistry Group, Institute of Biology Leiden, Leiden University, Leiden, Netherlands.ORCID http://orcid.org/0000-0002-3781-8223
Emma van GroesenBiological Chemistry Group, Institute of Biology Leiden, Leiden University, Leiden, Netherlands.ORCID http://orcid.org/0000-0003-2991-8256
Wiep Klaas SmitsCenter for Microbiome Analyses and Therapeutics, Leiden University Center for Infectious Diseases (LUCID), Leiden University Medical Center, Leiden, Netherlands.ORCID http://orcid.org/0000-0002-7409-2847
Casey M TheriotDepartment of Population Health and Pathobiology, College of Veterinary Medicine, NC State University, Raleigh, NC, USA.ORCID http://orcid.org/0000-0002-1895-8941
Nathaniel I MartinBiological Chemistry Group, Institute of Biology Leiden, Leiden University, Leiden, Netherlands. n.i.martin@biology.leidenuniv.nl.ORCID http://orcid.org/0000-0001-8246-3006

Funding

Nederlandse Organisatie voor Wetenschappelijk Onderzoek (Netherlands Organisation for Scientific Research) NACTAR 18504Nederlandse Organisatie voor Wetenschappelijk Onderzoek (Netherlands Organisation for Scientific Research) NACTAR 20813
6 · The paper itself

Abstract

Oral vancomycin has a long history as the first-line treatment for Clostridioides difficile infection (CDI), but its use is associated with high relapse rates. Antibiotics that more selectively target C. difficile while sparing protective commensal gut bacteria, have the potential to prevent recurrent CDI (rCDI). Here, we investigate the experimental glycopeptide antibiotic, EVG7, in the context of rCDI. In vitro susceptibility assays reveal that clinical C. difficile isolates are up to 16-times more sensitive to EVG7 (MIC = 0.063-0.25 mg/L) compared to vancomycin (MIC = 0.5-2 mg/L). In a validated mouse model of rCDI in male mice, low dose oral EVG7 (0.04 mg/mL in drinking water) more effectively treats primary CDI and prevents recurrence, outperforming a 10-fold higher dose of vancomycin. Subsequent microbiome analysis and in vitro susceptibility testing reveal that EVG7 preserves Lachnospiraceae, a family of commensal bacteria associated with protection against C. difficile colonization.

Indexed as

Anti-Bacterial AgentsClostridioides difficileClostridium InfectionsGlycopeptidesAnimalsDisease Models, AnimalGastrointestinal MicrobiomeHumansMaleMiceMice, Inbred C57BLMicrobial Sensitivity TestsRecurrenceVancomycinAnti-Bacterial AgentsGlycopeptidesVancomycin

Identifiers

PMID41073374
PMCPMC12514160

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.